The ASX-listed American shares for AVITA Medical (ASX:AVH) have seen an increase of up to 6.03% to A$5.67, a figure not reached since July 31.

This surge comes after the regenerative medicine company reported quarterly revenue of $11.7 million, effectively outdoing analysts' estimate of $11.3 million.

AVITA Medical also raised its full-year commercial revenue guidance to fall within the $51 to $53 million range, up from the previously anticipated $49 to $51 million.

Despite posting a net loss of $10.4 million in Q2, equating to a loss of $0.41 per share, as compared to last year’s net loss of $6.3 million, or $0.25 per share; the company’s stock has arisen 179.1% this year, till its most recent closing.

AVITA Medical is a U.S.

based company specializing in regenerative medicine.